Alex Sirois

Alex Sirois

InvestorPlace Contributor

Alex is a freelance contributor to InvestorPlace who provides investment insight that is conversational, actionable, and educational. While he writes about all stock classes, his personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks.

Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing. His number one goal in writing for InvestorPlace is to bring value to the reader.

You can follow Alex on LinkedIn.

Recent Articles

QuantumScape Stock Remains as Compelling as Ever, Meaning a 50/50 Chance

By Alex Sirois, InvestorPlace Contributor

QS stock should remain sideways until it proves something substantial. The future is 50/50 for the solid-state battery manufacturer.

Tilray Stock Doesn’t Have a Good Path Forward as Revenue Flags

By Alex Sirois, InvestorPlace Contributor

TLRY stock has no realistic path toward increased revenues and stock price. The $4 billion goal doesn't appear achievable.

Don’t Touch Dogecoin Despite Flaky Tweets From AMC CEO

By Alex Sirois, InvestorPlace Contributor

Dogecoin remains a hot topic as AMC CEO Adam Aron gave it some fuel recently. Don't bite at what he's offering.

Ocugen Still Lacks a Path to U.S. Profits

By Alex Sirois, InvestorPlace Contributor

Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock.

Novavax Is Looking More and More Like It Has Moderna-Type Potential

By Alex Sirois, InvestorPlace Contributor

NVAX stock has languished as FDA approval seemed less likely. But that has all changed now. Novavax is almost certainly headed higher.

Load More